Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses
Preprint
- 8 August 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Background: Tests for SARS-CoV-2 immunity are needed to help assess responses to vaccination, which can be heterogeneous and may wane over time. The plaque reduction neutralization test (PRNT) is considered the gold standard for measuring serum neutralizing antibodies but requires high level biosafety, live viral cultures and days to complete. We hypothesized that competitive enzyme linked immunoassays (ELISAs) based on SARS-CoV-2 spike protein’s receptor binding domain (RBD) attachment to its host receptor, the angiotensin converting enzyme 2 receptor (ACE2r), would correlate with PRNT, given the central role of RBD-ACE2r interactions in infection and published studies to date, and enable evaluation of vaccine responses.Methods and Findings: Configuration and development of a competitive ELISA with plate-bound RBD and soluble biotinylated ACE2r was accomplished using pairs of pre/post vaccine serum. When the competitive ELISA was used to evaluate N=32 samples from COVID-19 patients previously tested by PRNT, excellent correlation in IC50 results were observed (rs= .83, p < 0.0001). When the competitive ELISA was used to evaluate N=41 vaccinated individuals and an additional N=14 unvaccinated recovered COVID-19 patients, significant differences in RBD-ACE2r inhibitory activity were associated with prior history of COVID-19 and type of vaccine received. In longitudinal analyses pre and up to 200 days post vaccine, surrogate neutralizing activity increased markedly after primary and booster vaccine doses, but fell substantially, up to <12% maximal levels within 6 months.Conclusions: A competitive ELISA based on inhibition of RBD-ACE2r attachment correlates well with PRNT, quantifies significantly higher activity among vaccine recipients with prior COVID (vs. those without), and highlights marked declines in surrogate neutralizing activity over a 6 month period post vaccination. The findings raise concern about the duration of vaccine responses and potential need for booster shots.Keywords
Other Versions
- Published version: Version PLOS ONE, 17, preprints
This publication has 27 references indexed in Scilit:
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersThe New England Journal of Medicine, 2021
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assaysNature Protocols, 2021
- Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variantImmunity, 2021
- Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal studyThe Lancet Microbe, 2021
- An update to monoclonal antibody as therapeutic option against COVID-19Biosafety and Health, 2021
- Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we needSignal Transduction and Targeted Therapy, 2021
- Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack RateJournal of Clinical Microbiology, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptorNature Communications, 2020
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktailScience, 2020